|

ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)

RECRUITINGSponsored by Erasmus Medical Center
Actively Recruiting
SponsorErasmus Medical Center
Started2017-02-02
Est. completion2031-01-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05221372

Summary

The study is perfomed with adult patients with non-small cell lung cancer treated with tyrosine kinase inhibitor. The objective is to collect repeated samples of blood from patients (starting) on a tyrosine kinase inhibitor, for liquid mutation testing, and pharmacokinetic analysis.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥ 18 years
* Able to understand the written informed and able to give informed consent
* Locally advanced or metastatic NSCLC with oncogenic driver mutation
* Treatment with TKI according to standard of care

Exclusion Criteria:

* Unable to draw blood for study purposes

Conditions5

CancerLiquid BiopsyLung CancerNon Small Cell Lung CancerTyrosine Kinase Inhibitor

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.